Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Common Equity (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Common Equity readings, the most recent being $83.0 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 37.57% to $83.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.0 million, a 37.57% decrease, with the full-year FY2025 number at $83.0 million, down 37.57% from a year prior.
  • Common Equity hit $83.0 million in Q4 2025 for Avalo Therapeutics, down from $91.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $133.0 million in Q4 2024 to a low of -$112.5 million in Q1 2024.
  • Median Common Equity over the past 5 years was $17.9 million (2023), compared with a mean of $27.2 million.
  • The widest YoY moves for Common Equity: up 1721.36% in 2024, down 1695.79% in 2024.
  • Avalo Therapeutics' Common Equity stood at $23.1 million in 2021, then plummeted by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then skyrocketed by 1721.36% to $133.0 million in 2024, then tumbled by 37.57% to $83.0 million in 2025.
  • The last three reported values for Common Equity were $83.0 million (Q4 2025), $91.5 million (Q3 2025), and $104.6 million (Q2 2025) per Business Quant data.